… -sensitizing EGFR mutations were taken immediately before treatment with erlotinib.
Additional blood samples were taken at timed intervals until erlotinib treatment was withdrawn. …

… Large inter- and intrapatient pharmacokinetic variability was observed with oral erlotinib
treatment, although relatively dose-proportional increases are observed when doses are …

… growth factor receptor tyrosine kinase mutation. Two progressing patients exhibited epidermal
growth factor … Conclusions: Erlotinib shows significant antitumor activity in the first-line …

… The oral epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib has …
; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-…

… Erlotinib (Tarceva) is a specific epidermal growth factor … Gefitinib (Iressa) shares with erlotinib
both a common chemical … 2-fold less potent than erlotinib. Clinical studies have resulted in …

… growth factor receptor. We conducted a phase I/II trial to evaluate AUY922 and erlotinib …
patients with EGFR-mutant lung cancer and disease progression during erlotinib treatment. …

… epidermal growth factor receptor (EGFR) has become an important target in the treatment
of … inhibitors, with a focus on erlotinib, as first-line treatment towards a form of personalized …

… erlotinib compares with CT in EGFR-mutant Caucasian p. We have performed a prospective,
randomized phase III study comparing erlotinib … Erlotinib as first-line treatment for advanced …

… with the intracellular catalytic domain of epidermal growth factor receptor (HER1/EGFR)
tyrosine … Erlotinib treatment was generally well tolerated and the most commonly reported side …

… erlotinib. Extracellular binding of ligands like the epidermal growth factor (EGF) and transforming
growth factor-… survival, 31% of patients treated with erlotinib in this study were alive at 1 …